ALIVE Israel HealthTech Fund

ALIVE Israel HealthTech Fund operates as a dedicated investment platform, focusing on mid-to-late stage companies within the HealthTech sector. The fund targets MedTech, Digital Health, and Bio-convergence firms, emphasizing those poised for scaling. It differentiates itself by leveraging an exclusive network of strategic partners, including leading hospital chains and health maintenance organizations, to provide portfolio companies with an advantage in clinical viability, market relevance, and regulatory navigation.

The firm was established in 2020 by its co-founders, Prof. Ari Shamiss, Prof. Rafael Beyar, Michel Habib, and Dudi Klein. This founding team brings extensive collective experience in healthcare systems and a deep understanding of the US healthcare market. Their combined expertise forms the foundational insight for ALIVE, enabling a rigorous assessment of the potential for advanced health technologies to meet critical medical needs.

ALIVE backs companies that demonstrate strong clinical credibility and significant market potential. The fund’s approach involves active partnership with its portfolio founders and teams, aiming to transform technological innovation into practical, impactful solutions. Its long-term vision is centered on facilitating the development and deployment of deep technology to address substantial unmet clinical needs globally, driving tangible advancements in healthcare.